GleamWall
中文EN

INDP Indaptus Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1857044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.0%
TTM EPS YoY89.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-180.7%
ROA-70.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.9%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.34M$7.25M
SG&A expense$10.49M$8.11M
Operating income-$19.83M-$15.37M
Pretax income-$20.85M-$15.02M
Income tax$1,716$1,700
Net income-$20.85M-$15.02M
EBITDA—-$15.37M
EPS (basic)-21.58-44.96
EPS (diluted)-21.58-44.96
Weighted avg. shares (diluted)966,124334,133
Balance sheet
Cash & equivalents$8.51M$5.79M
Current assets$9.31M$6.62M
Total assets$9.31M$7.34M
Current liabilities$6.16M$3.39M
Total liabilities$6.16M$3.39M
Shareholders' equity$3.15M$3.94M
Shares outstanding2.17M428,799
Cash flow statement
Operating cash flow-$14.82M-$12.32M
Financing cash flow$17.54M$4.75M
Depreciation & amortization—$735
Stock-based compensation$1.36M$2.31M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.